StockMacro
Menu

Veradermics

$119.52 +17% in 6 monthsMarket cap $5.0B

MANE on XNYS, Health Care, Veradermics, Incorporated, job postings

Measures activity, not value. Not investment advice.

Insiders sold $75.2M in 90 days as shares fell 13% in a month, with a $93.6M 12-month loss.

  • BadFour share registrations and one private placement in 12 months
  • GoodInstitutional holders rose 28% last quarter, from 162 to 207

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

Industry
Pharmaceutical preparations (Health Care)
Employees
21
Website
veradermics.com
Listed
NYSE, US
Last results
10 Nov 2026
Next results
expected around 29 Mar 2027 (an estimate: a year ago it reported on 30 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $21.0M.
Quarter to 31 Mar 2025: revenue –, net income -$12.4MQuarter to 30 Jun 2025: revenue –, net income -$15.6MQuarter to 30 Sep 2025: revenue –, net income -$20.1MQuarter to 31 Dec 2025: revenue –, net income -$21.8MQuarter to 31 Mar 2026: revenue –, net income -$27.2MQuarter to 30 Jun 2026: revenue –, net income -$23.5MQuarter to 30 Sep 2026: revenue –, net income -$21.0M
31 Mar 2025RevenueNet incomeNet losstallest bar $27.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$21.0M
30 Jun 2026–-$23.5M
31 Mar 2026–-$27.2M
31 Dec 2025–-$21.8M
30 Sep 2025–-$20.1M
30 Jun 2025–-$15.6M
31 Mar 2025–-$12.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$93.6M –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $798.4M $5.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$798.4M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $18.88
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.3 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
VeradermicsMANE (this company) $5.0Bloss–––
LiquidiaLQDA $4.9Bloss7.9+798%-15.1%
ErascaERAS $4.8Bloss–––
Dianthus TherapeuticsDNTH $4.8Bloss–––
PTC TherapeuticsPTCT $4.7Bloss4.1-35%-9.2%
Cogent BiosciencesCOGT $4.6Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$75.2M

bought $0, sold $75.2M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+28%

207 13F filers vs 162

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

86.9M shares held by 13F filers (30 Sep 2026) of 42.2M outstanding (5 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.0%

3.4M shares sold short (30 Oct 2026) of 42.2M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.1

3.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-8.4%

3.7M shares sold short in the report before, 3.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

76%

76% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.3×

8 articles in the last 7 days; its usual week has 1.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • First lobbying new, first

Price $119.52 on 20 Nov 2026, +217% over 12 months (12-month range $37.03 to $156.56)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $142.5M in the last 12 months (the 12 months before: $0).
Capital spending per quarter. Capital spending $21K in the latest quarter.
Institutional holders (13F filers). 207 13F filers reported holding it in the latest 13F quarter, +159% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
14 Oct 2026Lobbying filingnew lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
14 Oct 2026Sharp changeFirst lobbying registration: first lobbying registration: VERADERMICS, INCORPORATED: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS)
7 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
15 May 20268-K and other filingsPrivate placement of securities (Form D)
27 Apr 20268-K and other filingsRegistered new securities for sale (S-1)
6 Feb 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 25.3M)
28 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
9 Jan 20268-K and other filingsRegistered new securities for sale (S-1)
28 Oct 20258-K and other filingsPrivate placement of securities (Form D)
10 Dec 20248-K and other filingsPrivate placement of securities (Form D)
1 May 20238-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Feb 2026: $35.8M published
Month from 1 Aug 2026: -$103.1M published
Month from 1 Nov 2026: -$75.2M published
Capital spending per quarter
Quarter ended 31 Mar 2025: $19K; public on 13 May 2026
Quarter ended 31 Dec 2025: $5K; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 13 May 2026
Quarter ended 30 Jun 2026: $21K; public on 12 Aug 2026
Institutional holders (13F filers)
31 Mar 2026 report: 80; public on 15 May 2026
30 Jun 2026 report: 162; public on 14 Aug 2026
30 Sep 2026 report: 207; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it registered for federal lobbying for the first time in our data (Checkmate Government Relations).
  • First lobbying registration: registered for federal lobbying for the first time in our data (Checkmate Government Relations) Public on 14 Oct 2026.
  • Insider net buying (open market): Insiders sold a net $142.5M in the last 12 months (the 12 months before: $0).
  • Capital spending per quarter: Capital spending $21K in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 12 insider trades

Last 90 days: 1 sale, $75.2M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Nov 2026Longitude Capital Partners V, LLC and 1 other10% ownerSell500,000$150.38$75.2MForm 4
21 Aug 2026Averill Master Fund, Ltd. and 3 othersDirectorSell750,000$107.25$80.4MForm 4
18 Aug 2026Reid Alexander WaldmanChief Executive OfficerSellplanned in advance (10b5-1); after exercising options67,500$107.86$7.3MForm 4
18 Aug 2026Timothy August DursoChief Technical OfficerSellplanned in advance (10b5-1); after exercising options43,500$107.82$4.7MForm 4
14 Aug 2026John W ChildsDirectorSell100,000$107.12$10.7MForm 4
9 Feb 2026Suvretta Capital Management, LLC and 3 othersDirector, 10% ownerBuy282,674$37.30$10.5MForm 4
5 Feb 2026Vlad CoricDirectorBuy117,646$17.00$2.0MForm 4
5 Feb 2026John W ChildsDirectorBuy294,117$17.00$5.0MForm 4

207 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 56 opened a position, 16 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Rakuten Investment Management, Inc.50.5M119.7%$19.0BNew+50.5M
Montanova Capital, LLC3.7M8.81%$450.9M-450K-11%
FMR LLC (Fidelity)3.1M7.26%$371.2M-143K-4.5%
JPMorgan Chase & Co2.4M5.62%$279.8M+1.2M+104%
Sr One Capital Management, LP2.1M4.93%$252.2M-322K-13%
Citadel Advisors LLC2.0M4.85%$248.3M+171K+9.1%
BlackRock, Inc.1.9M4.57%$234.0M+336K+21%
Deep Track Capital, LP1.9M4.50%$230.3M-100K-5.0%
Siren, L.L.C.1.3M3.14%$160.5M-331K-20%
D. E. Shaw & Co., Inc.1.3M3.00%$153.5M+253K+25%

Company events

All 11 company events

In 12 months: 4 share registrations, 1 major agreement, 1 private placement. Results releases and routine reports are left out.

FiledWhat happenedSource
7 Aug 2026Registered new securities for sale (S-1)S-1
15 May 2026Private placement of securities (Form D)$30.0M sold of $30.0M offeredD
1 May 2026Signed a major agreementSame filing: sold shares privately8-K
27 Apr 2026Registered new securities for sale (S-1)S-1
28 Jan 2026Registered new securities for sale (S-1)S-1/A
9 Jan 2026Registered new securities for sale (S-1)S-1
28 Oct 2025Private placement of securities (Form D)$135.0M sold of $150.0M offeredD
10 Dec 2024Private placement of securities (Form D)$66.6M sold of $75.0M offeredD

No lobbying spend reported yet. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
14 Sep 2026NewCheckmate Government Relationsfor Veradermics, IncorporatedIssues regarding advocacy related to hair loss treatmentHealth issues, PharmacyFiling

The 5 newest of 167 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 14 Oct 2026Lobbying change

    registered for federal lobbying for the first time in our data (Checkmate Government Relations).

    See the evidence (1 source record)
    Source coverage starts
    3 Jan 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  2. 14 Oct 2026Lobbying record

    VERADERMICS, INCORPORATED: new lobbying registration (CHECKMATE GOVERNMENT RELATIONS) (dated 14 Sep 2026)

  3. 7 Aug 2026Filings record

    Registered new securities for sale (S-1)

  4. 15 May 2026Filings record

    Private placement of securities (Form D)

  5. 27 Apr 2026Filings record

    Registered new securities for sale (S-1)

  6. 28 Feb 2026Insiders record

    CHILDS JOHN W (director) bought 294,117 shares of MANE ($5.0M) [amended] (dated 27 Feb 2026)

  7. 10 Feb 2026Insiders record

    SUVRETTA CAPITAL MANAGEMENT, LLC (director) and 3 other(s) bought 282,674 shares of MANE ($10.5M) (dated 9 Feb 2026)

  8. 6 Feb 2026Insiders change

    had 3 insiders buy $25.3M of its shares on the open market within 30 days (3 filings).

    Who bought: Enright Patrick G, Childs John W, Coric Vlad.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $25.3M
    Window
    7 Jan 2026 to 6 Feb 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  9. 6 Feb 2026Insiders record

    Coric Vlad (director) bought 117,646 shares of MANE ($2.0M) (dated 5 Feb 2026)

  10. 6 Feb 2026Insiders record

    Longitude Venture Partners V, L.P. (ten percent owner) and 3 other(s) bought 1,075,000 shares of MANE [same transaction as an earlier filing] (dated 5 Feb 2026)

  11. 6 Feb 2026Insiders record

    CHILDS JOHN W (director) bought 294,117 shares of MANE ($5.0M) (dated 5 Feb 2026)

  12. 6 Feb 2026Insiders record

    ENRIGHT PATRICK G (director) bought 1,075,000 shares of MANE ($18.3M) (dated 5 Feb 2026)

  13. 28 Jan 2026Filings record

    Registered new securities for sale (S-1)

  14. 9 Jan 2026Filings record

    Registered new securities for sale (S-1)

  15. 28 Oct 2025Filings record

    Private placement of securities (Form D)

  16. 10 Dec 2024Filings record

    Private placement of securities (Form D)

  17. 1 May 2023Filings record

    Private placement of securities (Form D)

  18. 6 Oct 2021Filings record

    Private placement of securities (Form D)

  19. 9 Oct 2020Filings record

    Private placement of securities (Form D)

Not listed: 20 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001827635
Ticker
MANE
Domain
veradermics.com
Hq location
CT|NEW HAVEN|06513 (1 unverified)
Lobbying client
veradermics
Name
Veradermics, Incorporated
  • Federal lobbying disclosures (LDA)1 record, 2 data points14 Sep 2026 to 30 Sep 2026
  • SEC Form 13F institutional holdings27 data points31 Mar 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)24 records9 Oct 2020 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)93 data points31 Dec 2023 to 5 Nov 2026
  • SEC Form 4 insider transactions12 records, 24 data points5 Feb 2026 to 13 Nov 2026
  • FINRA short interest (twice monthly)53 data points13 Feb 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)404 data points4 Feb 2026 to 20 Nov 2026